SCHEMBL8041273

SCHEMBL8041273

CN1CCc2c(c3ccccc3n2CC(O)c2ccccc2)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 3/20 0.68
GRIN2D O15399 1/20 0.64
GRIN3B O60391 1/20 0.64
GRIN1 Q05586 1/20 0.64
GRIN2A Q12879 1/20 0.64
GRIN2B Q13224 1/20 0.64
GRIN2C Q14957 1/20 0.64
GRIN3A Q8TCU5 1/20 0.64
ADRA2A P08913 2/20 0.64
ADRA1A P35348 2/20 0.64
CHRM2 P08172 1/20 0.64
HTR1A P08908 1/20 0.64
CHRM1 P11229 1/20 0.64
DRD1 P21728 1/20 0.64
SLC6A2 P23975 1/20 0.64
SLC6A4 P31645 1/20 0.64
OPRM1 P35372 1/20 0.64
DRD3 P35462 1/20 0.64
SLC6A3 Q01959 1/20 0.64
KCNH2 Q12809 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185830 0.92 GRIN2D (0.70) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3032023 0.89 GRIN1 (0.75) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1225397 0.87 BCHE (0.68) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL18477556 0.83 MAOA (0.71) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1225705 0.82 BCHE (0.66) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2174231 0.81 GRIN1 (0.71) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL15307999 0.81 GRIN2D (0.53) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3229857 0.80 GRIN2D (0.64) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL15307950 0.80 GRIN2D (0.50) BCHEGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13833960 0.79 HRH1 (0.52) BCHEGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017083242-A1 INHIBITORS OF SUPPRESSION OF TUMORIGENCITY 2 (ST2) AND METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-05-18 WO disclosed
US-20110039825-A1 LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE ALLA CHEM, LLC (US) 2011-02-17 US disclosed
US-20110039825-A1 LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE ALLA CHEM, LLC (US) 2011-02-17 US disclosed
EP-2236511-A2 LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF Alla Chem, LLC. (US) 2010-10-06 EP disclosed
WO-2009082268-A2 LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF ALLA CHEM, LLC (US) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039825-A1 LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE ADRB3, ADRA2C, ADRB2 BCHE 1686/4885GRIN2D 489/4885GRIN3B 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.